



BC Centre for Disease Control
Provincial Health Services Authority

Immunization Programs and Vaccine Preventable Diseases Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: March 8, 2023

Administrative Circular: 2023:08

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine Eligibility

- Footnote F has been updated to indicate “Individuals 12 years of age and older who received a monovalent product for their fall booster dose may be offered a bivalent product at least 6 months following their last dose.”
- Footnote G has been added to indicate “COVID-19 revaccination can occur as early as 3 months post HSCT or CAR-T cell therapy with monovalent COVID-19 mRNA vaccine, as bivalent COVID-19 mRNA vaccines are not authorized for use in the primary series.”

Please remove page numbers: 1-3 dated January 20, 2023
Please add new page numbers: 1-3 dated March 2023

COVID-19 mRNA Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) Adult/Adolescent

ADMINISTRATION: Footnote E on page 1 has been revised to indicate that the vaccine may be used for up to 18 months from the date of manufacture when stored at -90°C to -60°C.

Please remove page numbers: 1-4 dated January 27, 2023
Please add new page numbers: 1-4 dated March 2023

Page 1 of 3

COVID-19 Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) 5-11 Years of Age

ADMINISTRATION: Footnote E on page 1 has been revised to indicate that the vaccine may be used for up to 18 months from the date of manufacture when stored at -90°C to -60°C.

Please remove page numbers: 1-5 dated December 9, 2022

Please add new page numbers: 1-5 dated March 2023

Human Papillomavirus Vaccines

Human Papillomavirus Vaccine (Nonavalent): Gardasil®9

Pregnancy has been moved from CONTRAINDICATIONS to PRECAUTIONS in alignment with the Gardasil®9 product monograph. HPV vaccine continues to not be recommended in pregnancy. Individuals who become pregnant before series completion should defer immunization until no longer pregnant. In pregnant individuals who are inadvertently vaccinated, there is no need to consider any intervention except reassurance, as the vaccine has not been associated with teratogenicity. As the vaccine has not been causally associated with adverse outcomes of pregnancy or adverse events to the developing fetus and given the low rates of live births within the under 15 year age group, there is no expectation to screen for pregnancy prior to offering HPV vaccine within routine school-based programs (i.e., grade 6 and 9).

Please remove page numbers: 1-3 dated June 2022

Please add new page numbers: 1-3 dated March 2023

Human Papillomavirus Vaccine (Bivalent): Cervarix®

Cervarix® was used as part of a one-time publicly funded program in BC which started in April 2012 and ended when vaccine supply expired. As Cervarix® is no longer part of a publicly funded program in BC, the product page has been removed from the BC Immunization Manual.

Please remove page numbers: 1 & 2 dated January 2016

Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated January 20, 2023 and replace with the enclosed updated Title Page and Table of Contents dated March 2023.

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHS Sc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Population & Public Health Division:

Brian Sagar
Senior Director Communicable Disease,
Population and Public Health Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division